DRAM1 and glioblastoma: Thus, DRAM1 and other autophagy modulators, such as BRZ, can potentially affect lysosomal function and autophagic flux stability in GBM cells, providing an avenue for novel therapeutic interventions to halt GBM progression and improve patient outcomes.